Literature DB >> 23695528

CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes.

Jong R Kim1, Nathan C Horton, Stephen O Mathew, Porunelloor A Mathew.   

Abstract

OBJECTIVE AND
DESIGN: CS1 (CRACC, CD319, SLAMF7) is a member of the Signaling Lymphocyte Activation Molecule family expressed on immune cells mediating host defense. CS1 is a self-ligand and has both activating and inhibitory functions in Natural Killer cells. However, the function of CS1 in human monocytes is currently unknown. The objective of this study was to evaluate the control of CS1 surface expression in activated monocytes and to assess the effect of CS1 triggering on proinflammatory cytokine production by monocytes. MATERIAL, METHODS AND TREATMENT: Human monocytes were isolated from PBMC of healthy volunteers by magnetic depletion method or FACS sorting. The monocytes were cultured with or without LPS (1 μg/ml) in the presence or absence of various pharmacological inhibitors to inhibit NF-кB and PI3K signaling pathways. The cells were stimulated with anti-CS1 antibody or isotype control. Total RNA was extracted and RT-PCR was performed using specific primers for CS1 and EAT-2. Cell supernatants were collected and cytokine levels (TNF-α and IL-12p70) were determined by sandwich ELISA.
RESULTS: Our study revealed that adherent or LPS-activated monocytes express CS1, and CS1 induction is via NF-кB and PI3K pathways. Importantly, cross-linking CS1 resulted in reduced production of proinflammatory cytokines TNF-α and IL-12p70 by LPS-activated monocytes.
CONCLUSIONS: Our study demonstrated that CS1 plays an inhibitory role in human monocytes to control proinflammatory immune responses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695528     DOI: 10.1007/s00011-013-0632-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  51 in total

1.  Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily.

Authors:  K S Boles; P A Mathew
Journal:  Immunogenetics       Date:  2001       Impact factor: 2.846

2.  Activating interactions in human NK cell recognition: the role of 2B4-CD48.

Authors:  H Nakajima; M Cella; H Langen; A Friedlein; M Colonna
Journal:  Eur J Immunol       Date:  1999-05       Impact factor: 5.532

3.  Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP.

Authors:  S G Tangye; S Lazetic; E Woollatt; G R Sutherland; L L Lanier; J H Phillips
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

Review 4.  SLAM family receptors and SAP adaptors in immunity.

Authors:  Jennifer L Cannons; Stuart G Tangye; Pamela L Schwartzberg
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

5.  Ly6G+ neutrophils are dispensable for defense against systemic Listeria monocytogenes infection.

Authors:  Chao Shi; Tobias M Hohl; Ingrid Leiner; Michele J Equinda; Xiaozhou Fan; Eric G Pamer
Journal:  J Immunol       Date:  2011-10-05       Impact factor: 5.422

6.  Regulation of Toll-like receptors in human monocytes and dendritic cells.

Authors:  A Visintin; A Mazzoni; J H Spitzer; D H Wyllie; S K Dower; D M Segal
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

7.  Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling.

Authors:  Nisha Nanda; Patrick Andre; Ming Bao; Karl Clauser; Francis Deguzman; Duncan Howie; Pamela B Conley; Cox Terhorst; David R Phillips
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113

8.  Molecular basis of the dual functions of 2B4 (CD244).

Authors:  Lukasz K Chlewicki; C Alejandro Velikovsky; Vamsi Balakrishnan; Roy A Mariuzza; Vinay Kumar
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

Review 9.  The SLAM and SAP gene families control innate and adaptive immune responses.

Authors:  Silvia Calpe; Ninghai Wang; Xavier Romero; Scott B Berger; Arpad Lanyi; Pablo Engel; Cox Terhorst
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

10.  Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs.

Authors:  Jae Kyung Lee; Kent S Boles; Porunelloor A Mathew
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

View more
  19 in total

1.  Transcriptome analysis highlights the conserved difference between embryonic and postnatal-derived alveolar macrophages.

Authors:  Sophie L Gibbings; Rajni Goyal; A Nicole Desch; Sonia M Leach; Miglena Prabagar; Shaikh M Atif; Donna L Bratton; William Janssen; Claudia V Jakubzick
Journal:  Blood       Date:  2015-07-31       Impact factor: 22.113

2.  Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy.

Authors:  Yasser A Aldhamen; Sergey S Seregin; Charles F Aylsworth; Sarah Godbehere; Andrea Amalfitano
Journal:  Int Immunol       Date:  2013-12-27       Impact factor: 4.823

3.  SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.

Authors:  Patrick O'Connell; Yuliya Pepelyayeva; Maja K Blake; Sean Hyslop; Robert B Crawford; Michael D Rizzo; Cristiane Pereira-Hicks; Sarah Godbehere; Linda Dale; Peter Gulick; Norbert E Kaminski; Andrea Amalfitano; Yasser A Aldhamen
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

Review 4.  Elotuzumab as a novel anti-myeloma immunotherapy.

Authors:  Sabarinath Venniyil Radhakrishnan; Neelam Bhardwaj; Mary Steinbach; Janet Weidner; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

5.  SLAMF7 engagement superactivates macrophages in acute and chronic inflammation.

Authors:  Daimon P Simmons; Hung N Nguyen; Emma Gomez-Rivas; Yunju Jeong; A Helena Jonsson; Antonia F Chen; Jeffrey K Lange; George S Dyer; Philip Blazar; Brandon E Earp; Jonathan S Coblyn; Elena M Massarotti; Jeffrey A Sparks; Derrick J Todd; Deepak A Rao; Edy Y Kim; Michael B Brenner
Journal:  Sci Immunol       Date:  2022-02-11

Review 6.  CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

Authors:  Joseph D Malaer; Porunelloor A Mathew
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Authors:  Qingqing Cai; Meifeng Tu; Zijun Y Xu-Monette; Ruifang Sun; Ganiraju C Manyam; Xiaolu Xu; Alexander Tzankov; Eric D Hsi; Michael B Møller; L Jeffrey Medeiros; Chi Young Ok; Ken H Young
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

Review 8.  SLAMF6 in health and disease: Implications for therapeutic targeting.

Authors:  Burcu Yigit; Ninghai Wang; Roland W Herzog; Cox Terhorst
Journal:  Clin Immunol       Date:  2018-10-23       Impact factor: 3.969

9.  An integrative network analysis framework for identifying molecular functions in complex disorders examining major depressive disorder as a test case.

Authors:  Anup Mammen Oommen; Stephen Cunningham; Páraic S O'Súilleabháin; Brian M Hughes; Lokesh Joshi
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

10.  Age-related differences in neuroinflammatory responses associated with a distinct profile of regulatory markers on neonatal microglia.

Authors:  Leah B Christensen; Tyson A Woods; Aaron B Carmody; Byron Caughey; Karin E Peterson
Journal:  J Neuroinflammation       Date:  2014-04-04       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.